Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand-name drug

Equetro price, strengths & recalls

Brand of carbamazepine (generic)

Pharmacies pay $109.25 for 30 capsules of Equetro 100 mg (12 hr) extended-release capsule this week, and from $109.25 to $140.92 across its 3 priced strengths and forms. The generic, carbamazepine, costs pharmacies from $3.58. It is in shortage (being discontinued). It has 14 recalls on record, none ongoing. Its official label last changed on August 21, 2025.

Being discontinuedBrand
Pharmacies pay$109.25for 30 capsules of 100 mg (12 hr) extended-release capsule-0.3% in 4 weeks
Fair cash price
$136.14
Strengths
3
Makers
1
Updated
Nov 11

Equetro price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
100 mg (12 hr) extended-release capsule Brand$3.64$109.25 / 30 capsules-0.3%-1.4%
200 mg (12 hr) extended-release capsule Brand$4.17$125.22 / 30 capsules-0.3%+0.3%
300 mg (12 hr) extended-release capsule Brand$4.70$140.92 / 30 capsules-0.1%+0.5%

The lowest cost per capsule is 100 mg (12 hr) extended-release capsule at $3.64. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Equetro vs generic carbamazepine

Generics have the same active ingredient, strength and form, and FDA requires them to work the same way. What pharmacies pay for each, same quantity:

StrengthBrandGenericBrand costs
100 mg (12 hr) extended-release capsule$109.25$32.803.3x
200 mg (12 hr) extended-release capsule$125.22$30.984x
300 mg (12 hr) extended-release capsule$140.92$33.954.2x
GenericCarbamazepine prices

Supply status: shortages & recalls

In shortage3 products are short or being discontinued
3 ongoing recalls14 recalls on record

Shortages

  • Carbatrol, Capsule, Extended Release, 100 mg (NDC 54092-171-12)Takeda Pharmaceuticals USA Inc. · Being discontinued Dec 19, 2025 · Updated Dec 19, 2025Discontinuation of the manufacture of the drug
  • Carbatrol, Capsule, Extended Release, 300 mg (NDC 54092-173-12)Takeda Pharmaceuticals USA Inc. · Being discontinued Dec 19, 2025 · Updated Dec 19, 2025Discontinuation of the manufacture of the drug
  • Carbatrol, Capsule, Extended Release, 200 mg (NDC 54092-172-12)Takeda Pharmaceuticals USA Inc. · Being discontinued Dec 19, 2025 · Updated Dec 19, 2025Discontinuation of the manufacture of the drug

In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.

Recalls

Showing the 6 most relevant of 14 - all recalls.

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for equetro? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedAugust 21, 2025
Version10 of 9
EffectiveAug 19, 2025
Read the label

These highlights do not include all the information needed to use EQUETROn safely and effectively. See full prescribing information for EQUETRO.EQUETRO (carbamazepine) extended-release capsules, for oral useInitial U.S. Approval:1968

This drug has a boxed warning

WARNING:SERIOUS DERMATOLOGIC REACTIONS AND APLASTIC ANEMIA AND AGRANULOCYTOSIS

Serious Dermatologic Reactions and HLA-B*1502 Allele

Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson Syndrome (SJS), have occurredb in patients treated with carbamazepine. These syndromes may be accompanied by mucous membrane ulcers, fever, or painful rash. These reactions are estimated to occur in 1 to 6 per 10,000 new users in countries with mainly Caucasian populations, but the risk in patients of Asian descent is estimated to be about 10 times higher. There is a strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA-B gene. Test for HLA-B*1502, prior to initiating EQUETROin patients with an increased likelihood of carrying this allele. Avoid use of EQUETRO in patients testing positive for the allele unless the benefit clearly outweighs the risk. Discontinue EQUETRO if you suspect that the patient has a serious dermatologic reaction[see Warnings and Precautions (

5.1)].

Aplastic Anemia and Agranulocytosis

Aplastic anemia and agranulocytosis can occurduring treatment with EQUETRO. The risk of developing these reactions with EQUETRO is 5-8 times greater than in the general population. However, the overall risk in the general population is low (6 cases in a population of one million per year for agranulocytosis and two cases in a population of one million per year for aplastic anemia). Obtain a complete blood count before beginning treatment with EQUETRO, and monitor CBC periodically.

Consider discontinuing EQUETRO if significant bone marrow depression develops

[see Warnings and Precautions (

5.2)

].

WARNING:SERIOUS DERMATOLOGIC REACTIONSAND APLASTIC ANEMIA AND AGRANULOCYTOSIS

See full prescribing information for complete boxed warning.

Serious Dermatologic Reactions

• Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson Syndrome (SJS), have occurred with EQUETRO (

5.1)

• Patients of Asian ancestry have a 10-fold greater risk of TEN/SJS, compared to other populations. In genetically at-risk patients, test for the HLA-B*1502 allele prior to initiating EQUETRO (

2.1,

5.1)

• Discontinue EQUETRO if these reactions occur (

5.1)

Aplastic Anemia and Agranulocytosis

• Aplastic anemia and agranulocytosis occurred with EQUETRO (

5.2)

• Obtain complete pretreatment hematological testing. Consider discontinuing EQUETRO if significant bone marrow depression develops (

2.1,

5.2)

Recent major changes (as listed on the label)

Warnings and Precautions (

5.5) 10/2022

|

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA021710 · Validus Pharms
First approved
December 10, 2004 (22 years ago)
Latest approved change
October 14, 2022
Approved label
PDF, Oct 17, 2022
Generic makers
26 approved generic applications on the market

Equetro questions

How much does equetro cost without insurance?

Pharmacies pay about $109.25 for 30 capsules of equetro 100 mg (12 hr) extended-release capsule ($3.64 per capsule). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $136.14. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is there a generic for Equetro?

Yes: carbamazepine. Pharmacies pay from $3.58 for it. Compare carbamazepine prices.

Is equetro in shortage?

Yes. 3 products are listed as in shortage or being discontinued (being discontinued). See which ones.

Has equetro been recalled?

14 recalls on record, none ongoing. Recalls name specific lots - check yours.

When did the equetro label last change?

The official label was last updated on August 21, 2025 (version 10). See what changed.

Talk about equetro

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.